Synapse

← Clinical & Translational Immunology

Papers in Clinical & Translational Immunology

Page 3 · newest first

  1. Cellular models in autoinflammatory disease researchClinical & Translational Immunology · 2024
  2. Engineered CAR‐T cells targeting the non‐functional P2X purinoceptor 7 (P2X7) receptor as a novel treatment for ovarian cancerClinical & Translational Immunology · 2024
  3. Effective γδ T‐cell clinical therapies: current limitations and future perspectives for cancer immunotherapyClinical & Translational Immunology · 2024
  4. Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastomaClinical & Translational Immunology · 2024
  5. Characteristics of PD‐1⁺CD4⁺ T cells in peripheral blood and synovium of rheumatoid arthritis patientsClinical & Translational Immunology · 2024
  6. Squamous cell carcinoma is associated with reduced IL34 expression, alterations in the Langerhans cell antigen‐processing‐presentation machinery and poor patient survivalClinical & Translational Immunology · 2024
  7. Primary SARS‐CoV‐2 infection in children and adults results in similar Fc‐mediated antibody effector function patternsClinical & Translational Immunology · 2024
  8. Exploring NK cell receptor dynamics in paediatric leukaemias: implications for immunotherapy and prognosisClinical & Translational Immunology · 2024
  9. Advances in bacteria‐based drug delivery systems for anti‐tumor therapyClinical & Translational Immunology · 2024
  10. Siglec‐1, an easy and contributory inflammation marker in rheumatologyClinical & Translational Immunology · 2024
  11. γδ T cells mediate robust anti‐HIV functions during antiretroviral therapy regardless of immune checkpoint expressionClinical & Translational Immunology · 2024
  12. Humoral and cellular immune responses in vaccinated and unvaccinated children following SARS‐CoV‐2 Omicron infectionClinical & Translational Immunology · 2024
  13. From the bench to the clinic: basophils and type 2 epithelial cytokines of thymic stromal lymphopoietin and IL‐33Clinical & Translational Immunology · 2024
  14. Maintenance of caecal homeostasis by diverse adaptive immune cells in the rhesus macaqueClinical & Translational Immunology · 2024
  15. CD39 expression defines exhausted CD4⁺ T cells associated with poor survival and immune evasion in human gastric cancerClinical & Translational Immunology · 2024
  16. Whole blood transcriptomics reveals granulocyte colony‐stimulating factor as a mediator of cardiopulmonary bypass‐induced systemic inflammatory response syndromeClinical & Translational Immunology · 2024
  17. From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019Clinical & Translational Immunology · 2024
  18. Phenotypic spectrum in a family with a novel RAC2 p.I21S dominant‐activating mutationClinical & Translational Immunology · 2024
  19. Autologous Epstein–Barr virus‐specific adoptive T‐cell therapy in a patient with lupus nephritisClinical & Translational Immunology · 2024
  20. Chitinase 3‐like 1 expression associated with lymphatic metastasis and prognosis in urothelial carcinoma of the bladderClinical & Translational Immunology · 2024
  21. Spatial proteomic profiling of tumor and stromal compartments in non‐small‐cell lung cancer identifies signatures associated with overall survivalClinical & Translational Immunology · 2024
  22. Effects of extremely preterm birth on cytokine and chemokine responses induced by T‐cell activation during infancyClinical & Translational Immunology · 2024
  23. High KRT17 expression in tumour budding indicates immunologically ‘hot’ tumour budding and predicts good survival in patients with colorectal cancerClinical & Translational Immunology · 2024
  24. Whole transcriptome profiling of placental pathobiology in SARS‐CoV‐2 pregnancies identifies placental dysfunction signaturesClinical & Translational Immunology · 2024
  25. A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancerClinical & Translational Immunology · 2024
  26. Optimisation of a primary human CAR‐NK cell manufacturing pipelineClinical & Translational Immunology · 2024
  27. Characterisation of circulating tumor‐associated and immune cells in patients with advanced‐stage non‐small cell lung cancerClinical & Translational Immunology · 2024
  28. SARS‐CoV‐2‐infected human airway epithelial cell cultures uniquely lack interferon and immediate early gene responses caused by other coronavirusesClinical & Translational Immunology · 2024
  29. Unremitting pro‐inflammatory T‐cell phenotypes, and macrophage activity, following paediatric burn injuryClinical & Translational Immunology · 2024
  30. CD177 drives the transendothelial migration of Treg cells enriched in human colorectal cancerClinical & Translational Immunology · 2024
  31. Naturally acquired adaptive immunity to Streptococcus pneumoniae is impaired in rheumatoid arthritis patientsClinical & Translational Immunology · 2024
  32. Dual CD47 and PD‐L1 blockade elicits anti‐tumor immunity by intratumoral CD8⁺ T cellsClinical & Translational Immunology · 2024
  33. Identification of distinct immune signatures in inclusion body myositis by peripheral blood immunophenotyping using machine learning modelsClinical & Translational Immunology · 2024
  34. Inhibitory effect of hydroxychloroquine on glucocorticoid‐induced osteoporosis in lupus therapyClinical & Translational Immunology · 2024
  35. Anti‐signal recognition particle antibodies induce cardiac diastolic dysfunction via oxidative stress injuryClinical & Translational Immunology · 2024
  36. Autoantibodies in hospitalised patients with COVID‐19Clinical & Translational Immunology · 2024
  37. Natural killer cell antibody‐dependent cellular cytotoxicity to Plasmodium falciparum is impacted by cellular phenotypes, erythrocyte polymorphisms, parasite diversity and intensity of transmissionClinical & Translational Immunology · 2024
  38. Infiltrating characteristics and prognostic value of tertiary lymphoid structures in resected gastric neuroendocrine neoplasm patientsClinical & Translational Immunology · 2024
  39. Plasma EBV quantification is associated with the efficacy of immune checkpoint blockade and disease monitoring in patients with primary pulmonary lymphoepithelioma‐like carcinomaClinical & Translational Immunology · 2024
  40. Serological responses and clinical outcomes following a three‐dose primary COVID‐19 vaccine schedule in kidney transplant recipients and people on dialysisClinical & Translational Immunology · 2024
  41. Prediction of intravenous immunoglobulin retreatment in children with Kawasaki disease using models combining lymphocyte subset and cytokine profile in an East Asian cohortClinical & Translational Immunology · 2024
  42. Graft CD8 T‐cell‐based risk system predicts survival in antithymocyte globulin‐based myeloablative haploidentical peripheral blood stem cell transplantationClinical & Translational Immunology · 2024
  43. Immunoglobulin G genetic variation can confound assessment of antibody levels via altered binding to detection reagentsClinical & Translational Immunology · 2024
  44. Dupilumab improves outcomes in patients with chronic rhinosinusitis with nasal polyps irrespective of gender: results from the SINUS ‐52 trialClinical & Translational Immunology · 2024
  45. Improving diagnosis in patients with obstetric antiphospholipid syndrome through the evaluation of non‐criteria antibodiesClinical & Translational Immunology · 2024
  46. Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individualsClinical & Translational Immunology · 2024
  47. A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignanciesClinical & Translational Immunology · 2024
  48. CD14 down‐modulation as a real‐time biomarker in Kawasaki diseaseClinical & Translational Immunology · 2023
  49. A novel dual NLRP1 and NLRP3 inflammasome inhibitor for the treatment of inflammatory diseasesClinical & Translational Immunology · 2023
  50. Adoptive T‐cell therapy targeting Epstein–Barr virus as a treatment for multiple sclerosisClinical & Translational Immunology · 2023